Maxcyte Share Discussion Threads

[adamb1978] 01/10/2021 16:23

Trident

OK. You seem to have a grudge against this company given you regularly post negative comments on here. I'm all for two-sided debates, and discussion over the pros and cons of a company (and one of the weaknesses of advfn is that there are too many boards with people constantly high-fiving and exaggerating a company's potential) however when someone spends so much time posting negatively about a company, it suggests some undisclosed motive as I cant see why anyone sane would waste energy on something which didnt matter to them.

I'm therefore going to put you on filter and leave you to debate with others.
All the best for the future,

Adam

[rgmgo] 01/10/2021 16:21

It never rains, but it pours. hxxps://www.wsj.com/articles/deaths-raise-safety-concerns-around-gene-therapy-11633080601 If you can't access the article you can also try searching by the title: Deaths Raise Safety Concerns Around Gene Therapy. I guess at least we can say that the risk reward is getting interesting again, industry wide concerns are the biggest single threat to MXCT but having raised US capital at a premium to the current price, equity value has taken quite a thump at a time the company has continued to expand its pipeline of potential SPL partner royalties.

[trident5] 01/10/2021 16:04

Adam - yes just out. After reading about it elsewhere - that's not good.

I notice that after standing down his stock options continue to vest.

And my comment about 7 NEDs was sarcastic. This is a very small company and outsiders had to tell them to keep CARMA for the licensing revenue - so I'm not sure what value they add.

[adamb1978] 01/10/2021 16:00

Trident5 - they have, and obviously they'll appoint another Chairman.

And 7 NEDs is fine! 'Just' 7 NEDs??!? Not sure whether that was a sarcastic comment

[adamb1978] 01/10/2021 15:59

The chairman standing down I dont see as a problem - he's in his 70s and the Nasdaq listing should now help them to secure a decent successor.

Lots of growth stocks are getting whacked at the moment. Zoom is down over 50% from its highs. BLI is down over 80%!

Clearly these sort of drops aren't nice but if you're in this for the long-term, then hopefully it should be an irrelevance

[trident5] 01/10/2021 15:52

Why haven't Maxcyte issued an RNS telling us that the Chair is stepping down?

If they don't replace him they'll be down to just 7 NEDs.

[nimbo1] 01/10/2021 15:45

I think there a couple of other things impacting sentiment on top of general market sell off... Berkeley lights short report from a couple of weeks back (nothing to do with maxcyte) but charts look remarkably similar since and negative article in Wall Street journal on gene editing.

[acuere] 01/10/2021 15:43

News that the Chairman is stepping down seems to be the catalyst for todays kicking on the Nasdaq.
Company needs to announce some more SPLs to keep growth story alive. I was disappointed in the H1 results that the potential clinical programs were now over 75. At the previous results there were over 100.

[mysteronz] 01/10/2021 15:30

A few more added just now - £200m in cash don’t forget!

[adamb1978] 29/9/2021 15:57

The price is coming off simply because 10 yr yields are increasing, which hits growth stocks. I'm not sure it is anything more than that

[rgmgo] 29/9/2021 14:48

I think we have to recognise that there are a lot of moving parts with the MXCT story and we are still at an early stage, so volatility will likely continue to be high. Moving back to a discussion of the technology I think something to watch (admittedly over the next decade or so....) is the risk of chromothripsis discussed in this article Crispr: Bad News For Gene Editing The associated disussion is also worth wading through, although rather like this forum includes nuggets but also a few too many brickbats. IMHO, even if there proves to be an issue there may be an argument for proceding with treatment for patients with chronic disease, against an apparently modest (but non trivial) risk of developing another serious illness many years down the line. MXCT also potentially benefits from the diversity of its partnerships. Restriction enzymes like those deployed by partner Precision Biosciences may be less vulnerable to chromothripsis complications than Crispr Cas9. It would also be reassuring if Beam Therapeutics ever progresses to a MXCT SPL (we know it uses electroporation in its pre clinical work in hematology and oncology) as Beam's base editing technology does not require a double helix break.

[trident5] 29/9/2021 11:43

Agreed. But there were peeps on here who have been constantly stating that an American listing would drive the price up. It hasn't.

Elsewhere on these boards this argument is frequently made but never seems to deliver, and investors should be wary of it.

Of course, we don't know the counterfactual - if it hadn't listed the price could be even lower, but we do know that our slices of the pie would not have reduced.

[nimbo1] 29/9/2021 11:40

At this point its a fair comment - I hoped the price would double after US IPO...however the price did very well before had and clearly a lot has been priced in already. I would point out this is following a similar path timing wise to renx...and that did indeed double after a period of weakness post US IPO. So who knows what will happen.

I've now seen about 6 tweets Maxcyte have posted of themselves ringing the closing bell on nasdaq looking a bit too pleased with themselves for my liking! 1 is fine of course...

[mysteronz] 29/9/2021 09:50

If you care about a 3 month timeline, most serious investors will be here for 3+ Years

[trident5] 29/9/2021 09:09

Well, that US placing worked out just fine.

[trident5] 17/9/2021 17:45

I much prefer CEOs who ignore the share price/action and focus on running the business.
I can't see how being included in a stock index marks a milestone in platform technology - that's BS.

[pob69] 17/9/2021 13:39

MaxCyte Set to Join Russell 2000® Index (the Russell small cap index)

“The addition of MaxCyte to the Russell indices highlights our strong financial profile and marks a milestone in our progress towards being the premier cell engineering platform technology,” said Doug Doerfler, President and Chief Executive Officer of MaxCyte. “Our inclusion follows the successful closing of our Nasdaq IPO in August and elevates the overall awareness of our stock amongst the investment community.”

[pogue] 14/9/2021 19:32

I read most of the notes from the call I believe 2 companies maybe hitting significant milestones later this year or next, but what if they fail the clinical trials? They will not pass on a milestone payment. There is a downside risk as I say the price seems to put in a lot of upside already.
Its a great business model that will succeed but for just now I feel its ahead of itself and could suffer in any market dash for safety.

[adamb1978] 14/9/2021 11:41

Hi Pogue

There was a comment from the CEO on the call last night about milestone payments accelerating next year I think - I didnt hear it clearly but its worth having a listen for that comment on the call if you listen back to it.

Agreed that the multiple looks lofty at the moment for UK markets...however this goes to why they've listed on Nasdaq. UK markets just dont value this sort of business well, which is why its pleasing to me that volumes seem to be moving state-side.

Whether that was meant to cause a re-rating as you say, or just support the valuation....or just a recognition that if they want to be a major player in this area then they need to be US listed to have credibility (otherwise they're invisible in the sector)....plus perhaps that if they need to raise more capital in future, they're better off in the US. Or a combination of each of those

I dont really have a near-term view on the price. It definitely has had a good run but equally I'm always wary about taking money off the table on companies where the story hasnt changed as its harder to get back in (plus if you sell company A, then there's a risk that that sale is wrong and also a risk that the decision to buy company B in its place is wrong)

I'm personally planning to hold these until the story changes

Adam

[pogue] 14/9/2021 11:33

I think the problem is that the market cap of £1 billion has a lot of milestone payments baked in but the amount rolling in is not that much. If there is a change in market sentiment then this could look a little speculative and be sold down. Its move to the NASDAQ was supposed to rerate it as the Yanks are more able to see potential but even they are not piling in at these levels.
I am pretty sure it will be big at some point but I feel the same as DP and think the risks are to the downside short term and I am wary of the market caps at the moment for many companies.

[adamb1978] 14/9/2021 11:05

Interesting that the US volumes are 3x the UK volumes (at least based on last 3m trading averages). I think that helps from a valuation perspective given US holders will be move used to higher valuations

[donald pond] 14/9/2021 11:02

I've got no doubt I'll be back, it's a great company.

[mysteronz] 14/9/2021 10:31

All the best Donald, glad you have done well, they beat considerably on revenue so not sure what you were expecting. It’s the milestone revenue which is what will make this company at 100% flow through to the bottom line.

All the best with whatever you put your profits into.

[donald pond] 14/9/2021 09:45

Tbh I was a bit underwhelmed by the results. I think the company will be a success but the valuation is very rich atm and if there's any wobble in the markets it feels vulnerable so I took profits today but will keep a close eye on